UK ADPKD (Autosomal dominant polycystic kidney disease) Drugs Market Report 2023 to 2030

UK ADPKD (Autosomal dominant polycystic kidney disease) Drugs Market Analysis

$ 3999

UK ADPKD (Autosomal dominant polycystic kidney disease) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for drugs to treat polycystic kidney disease is driven by an increase in patients who require dialysis or renal failure. A significant factor influencing the growth rate of the polycystic kidney disease (PKD) drugs market is the rise in healthcare spending, which helps to improve its infrastructure. Major global players in ADPKD (Autosomal dominant polycystic kidney disease) Drugs Market are Otsuka Pharmaceutical Co., Ltd., Regulus Therapeutics, Palladio Biosciences, Reata Pharmaceuticals, Inc., Galapagos NV, AceLink Therapeutics, Inc., Exelixis, Inc, XORTX Therapeutics Inc., Sanofi S.A., PanoTherapeutics, Inc.

ID: IN10GBRD072 CATEGORY: Rare Diseases GEOGRAPHY: UK AUTHOR: Sakshi Mantri

Buy Now

UK ADPKD (Autosomal dominant polycystic kidney disease) Drugs Market Analysis Summary

UK ADPKD (Autosomal dominant polycystic kidney disease) Drugs Market is valued at around $7.54 Mn in 2022 and is projected to reach $21.36 Mn by 2030, exhibiting a CAGR of 13.9% during the forecast period 2023-2030.

Autosomal dominant polycystic kidney disease is the most common hereditary kidney disease and one of the most common, potentially fatal genetic disorders in people (ADPKD). Significant intra- and interfamilial variation is associated with it, which is mostly explained by its genetic heterogeneity and modifier genes. Since there is currently no effective treatment for ADPKD, the majority of efforts are concentrated on preventing complications, reducing cyst formation, and delaying the eventual progression to kidney failure. Since hypertension is the most common complication associated with ADPKD and manifests early in the course of the disease, antihypertensive medications and diuretics have historically dominated the ADPKD drugs market. This multifactorial issue often causes left ventricular hypertrophy, rapid renal function decline to ESRD, and cardiovascular death. The only medication authorized to treat individuals with autosomal dominant polycystic kidney disease who experience rapid disease progression is tolvaptan, a vasopressin 2 receptor antagonist. Tolvaptan's poor tolerability as a result of aquaretic effects and possible hepatotoxicity restricts its use. It is crucial and difficult to find new medications that can slow the progression of autosomal dominant polycystic kidney disease.

The market for drugs to treat polycystic kidney disease is driven by an increase in patients who require dialysis or renal failure. A significant factor influencing the growth rate of the polycystic kidney disease (PKD) drugs market is the rise in healthcare spending, which helps to improve its infrastructure. Major global players in ADPKD (Autosomal dominant polycystic kidney disease) Drugs Market are Otsuka Pharmaceutical Co., Ltd., Regulus Therapeutics, Palladio Biosciences, Reata Pharmaceuticals, Inc., Galapagos NV, AceLink Therapeutics, Inc., Exelixis, Inc, XORTX Therapeutics Inc., Sanofi S.A., PanoTherapeutics, Inc.

Market Dynamics

Market Drivers

An increase in individuals needing dialysis or experiencing renal failure is what is driving the market for medications to treat polycystic kidney disease. Due to a number of variables, including renal failure, a rare genetic mutation, a family history of kidney issues, and persons who get dialysis, the prevalence of polycystic kidney disease is increasing. Also, the market for treatments for polycystic kidney disease (PKD) is growing rapidly as a result of the increase in healthcare spending, which contributes to the development of the industry's infrastructure. In addition, the industry for the treatment of polycystic kidney disease (PKD) will expand as a result of enhanced awareness-raising initiatives by both public and private organizations. The market for polycystic kidney disease (PKD) will expand as a result of rising demand for innovative treatments, rising disposable income, and innovative solutions.

Market Restraints

However, the high expense of treating polycystic kidney disease (PKD) will impede market expansion. The market for polycystic kidney disease (PKD) will face challenges because of a shortage of highly qualified workers and a lack of healthcare infrastructure in developing nations. Lack of knowledge and COVID-19's impact on the supply chain will both constrain and impede the market's expansion.

Key players

Intercept Pharmaceuticals Madrigal Pharmaceuticals Astellas Pharma Ionis Pharmaceuticals Alnylam Pharmaceuticals Pfizer Novartis Sanofi Shire Alexion Pharmaceuticals

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UK ADPKD (Autosomal dominant polycystic kidney disease) Drugs Market Segmentation

By Treatment:

Medication
Surgery
Others

By Route of Administration:

Oral
Parenteral
Others

By End Users:

Hospitals
Clinics
Specialized treatment centers
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.